Efficacy and Safety of the Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Initially Unresectable Biliary Tract Cancer
Latest Information Update: 31 Jan 2023
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
- Indications Biliary cancer; Carcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 24 Jan 2023 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 24 Jan 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 24 Jan 2023 Status changed from recruiting to active, no longer recruiting.